All In Biotech

Investigational drug · Phase 2

Personalized Neoantigen Peptide Vaccine

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumors, Advanced Cancer, Recurrent Cancer.

Phase 2

Last checked: Nov 20, 2026Latest source record: Jul 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

55

Any phase or sponsor naming "Personalized Neoantigen Peptide Vaccine"

First trial start

2022

Nov 24, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Personalized Neoantigen Peptide Vaccine", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Solid Tumors
  • Advanced Cancer
  • Recurrent Cancer
  • Neoantigen-Specific Immunotherapy
  • Personalized Cancer Vaccine
  • Cancer
  • Solid Tumor, Adult

Approved drugs for the same conditions: Oncology · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "Personalized Neoantigen Peptide Vaccine" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Solid Tumors

  • 9MW2821Phase 311 trials

    Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer

  • ZG005Phase 311 trials

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer

  • AtirmociclibPF-07220060Phase 39 trials

    Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

  • FavezelimabMK-4280, MK-4820APhase 39 trials

    Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors

  • DivarasibGDC-6036, RO7435846Phase 38 trials

    Roche (Genentech) · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer, Non-small Cell Lung Cancer

  • HRS-7058Phase 35 trials

    Shandong Suncadia Medicine Co., Ltd. · KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment, Solid Tumors, Pancreatic Cancer

  • IpatasertibRO5532961, GDC-0068Phase 35 trials

    Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer

  • DB-1311BNT324Phase 34 trials

    BioNTech SE · Metastatic Castration-resistant Prostate Cancer, Advanced Lung Cancer, Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.